Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases

Walls, J.; Assiri, Adel M. A.; Howell, Anthony; Rogers, Eamonn; Ratcliffe, W A; Eastell, Richard; Bundred, NJ

doi:10.1038/sj/bjc.6690496

Cited by 4 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 In a study of 36 breast carcinoma patients with bone metastases, both PYD and DPD excretion increased in those patients with progressive disease ( P < 0.03 at 8 weeks). 46 In contrast, levels of PYD and DPD did not appear to change significantly in responding patients. These bone resorption markers have demonstrated a good correlation with clinical outcome and appear to be much more sensitive to changes in bone metabolism compared with traditional bone markers.…”

Section: Bone Resorption Markersmentioning

confidence: 87%

“…22 These new markers include several unique breakdown products of Type I collagen, including the pyridinium crosslinks pyridinoline (PYD) and deoxypyridinoline (DPD), and the peptide‐bound crosslinks N‐ telopeptide (NTX) and C‐telopeptide (CTX). 22, 43–46 In comparison with calcium and hydroxyproline, these collagen breakdown products are more specific to bone and do not appear to be influenced by diet or metabolism. 25…”

Section: Bone Resorption Markersmentioning

confidence: 99%

See 1 more Smart Citation

The clinical use of bone resorption markers in patients with malignant bone disease

Coleman

2002

Cancer

View full text Add to dashboard Cite

BACKGROUND Advanced tumors often metastasize to bone, resulting in a variety of skeletal complications. Bisphosphonates are potent inhibitors of osteoclast‐mediated bone resorption that reduce the incidence and delay the onset of skeletal complications and reduce the need for radiation and surgery. Biochemical markers of bone resorption have been identified that can augment the imaging techniques used to diagnose bone metastases and assess response to bisphosphonate therapy. METHODS In the current study, the available literature regarding bone resorption markers is reviewed and the clinical relevance of these data with respect to the treatment of bone metastases discussed. RESULTS Urinary calcium and hydroxyproline have been widely used to assess bone metabolism, but do not appear to be well correlated with clinical outcome in patients with bone metastases. Several unique breakdown products of Type I collagen (including pyridinium crosslinks, pyridinoline, and deoxypyridinoline) and peptide‐bound crosslinks (N‐telopeptide and C‐telopeptide) are more specific and sensitive markers of bone resorption. N‐telopeptide and C‐telopeptide have been identified as the most sensitive biochemical markers currently available for detecting bone metastases and for assessing response to therapy or disease progression. CONCLUSIONS To the author's knowledge markers of bone resorption have not yet been recommended for routine clinical use. However, further research is needed to define their potential role in the diagnosis of bone metastases, the assessment of disease progression and response to bisphosphonate therapy, and predict the rate of bone loss and the potential for fracture. Suppression of bone resorption markers in response to bisphosphonate therapy appears to correlate with clinical outcome in patients with both osteolytic and blastic bone lesions; therefore, the goal of bisphosphonate therapy should be to suppress markers of bone resorption. Cancer 2002;94:2521–33. © 2002 American Cancer Society. DOI 10.1002/cncr.10522

show abstract

Section: Bone Resorption Markersmentioning

confidence: 87%

Section: Bone Resorption Markersmentioning

confidence: 99%

The clinical use of bone resorption markers in patients with malignant bone disease

Coleman

2002

Cancer

View full text Add to dashboard Cite

show abstract

“…Some researchers has reported that the sensitivity of markers of bone resorption was 50-80%. 6,10 Bombardieri et all. showed that sALP was not as valuable markers of disease activity as markers of bone degradation in their study.…”

Section: Discussionmentioning

confidence: 98%

“…alkaline phosphatase, are not as valuable markers of disease activity as markers of bone degradation such as urinary pyridinoline (uPYR) and urinary deoxypyridinoline (uDPD). 6 uPYR and uDPD is formed during the posttranslational phase of collagen synthesis and is corporated into the bone matrix as a component of collagen molecules. Whereas uPYR is widely distributed throughout the body tissues, uDPD is only found in collagen of bone and dentin.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of urinary pyridinoline for determining bone metastasis in patients with non-metastatic breast cancer

Giniş

Sezer²,

Özdemir³

et al. 2011

J Clin Exp Invest

View full text Add to dashboard Cite

Amaç: Bu çalışmada metastazı olmayan meme kanserli hastalarda idrar piridinolin, deoksipiridinolin ve serum alkalen fosfataz düzeyleri ölçüldü ve 6 yıllık takipte kemik metastazının biyokimyasal belirteçleri olarak idrar piridinolin ve deoksipiridinolinin rolü değerlendirildi.Gereç ve yöntem: Çalışma kemik metastazı olmayan 34 hasta ve kontrol grubu olarak 40 sağlıklı bireyi içermektedir.Bulgular: Serum ALP hariç idrar piridinolin ve deoksipiridinolin düzeyleri kemik metastazı olmayan hastalarda kontrol grubundan belirgin olarak yüksekti. 6 yıllık takip sonucunda hastaların %20.5'da metastaz olduğu belirlendi. Metastaz tiplerinin dağılımı: %2.9 lokal, %2.9 karaciğer, %5.9 akciğer ve %8.8 kemik metastazı. Piridinolin için 43 pmol/ µmol kreatinin cut off değerinin sensitiivtesi %82 ve spesifitesi %80 olarak belirlendi. Deoksipiridinolin için 9.53 pmol/ µmol kreatinin cut off değerinin sensitiivtesi %76 ve spesifitesi %72 olarak belirlendi.Sonuç: Bu çalışma idrar çapraz bağlarının ölçümünün meme kanserinde kemiğe metastatik yayılımın erken belirlenmesine katkıda bulunabileceğini gösterdi. Ancak geniş ölçekli gruplarla ileri çalışmalar yapılmalıdır.

show abstract

“…[16], and the impact of various bisphosphonates on the inhibition of this process can be monitored by measuring several specific markers of bone resorption [22][23][24][25][26]. These specific markers include several unique breakdown products of type I collagen, including the pyridinium cross-links, pyridinoline and deoxypyridinoline, and the peptide-bound cross-links, N-telopeptide and C-telopeptide [22][23][24][25][26]. The effects of bisphosphonates on bone resorption were initially thought to result primarily from the physicochemical effect on the structure of hydroxyapatite crystals, but their molecular and cellular effects on osteoclasts have gradually been elucidated.…”

Section: Bisphosphonatesmentioning

confidence: 99%

The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy

Major

2002

The Oncologist

View full text Add to dashboard Cite

Background. Hypercalcemia of malignancy is a serious complication of cancer that affects patients with and without bone metastases. A single infusion of pamidronate disodium, a nitrogen-containing bisphosphonate, effectively normalizes serum calcium in the majority of patients treated for up to 1 month. Zoledronic acid is a new-generation, heterocyclic nitrogen-containing bisphosphonate and the most potent inhibitor of bone resorption identified to date.Methods. The natural history, clinical presentation, and treatment of hypercalcemia of malignancy are reviewed, with a focus on the mechanisms of action and relative efficacy and safety of bisphosphonate therapies.

show abstract

Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases

Cited by 4 publications

References 9 publications

The clinical use of bone resorption markers in patients with malignant bone disease

The clinical use of bone resorption markers in patients with malignant bone disease

Diagnostic value of urinary pyridinoline for determining bone metastasis in patients with non-metastatic breast cancer

The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy

Contact Info

Product

Resources

About